• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form F-3/A filed by SOPHiA GENETICS SA

    7/22/24 8:57:06 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SOPH alert in real time by email
    F-3/A 1 dp214630_f3a-2.htm FORM F-3/A

     

    Ent fAs  filed with the Securities and Exchange Commission on July 22, 2024.

     

     

    Registration No. 333-280060

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________________

     

    Amendment No. 2 to

     

    FORM F-3

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    _________________________

     

    SOPHiA GENETICS SA

    (Exact name of Registrant as specified in its charter)

     

    Switzerland   Not Applicable
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)


     

    La Pièce 12
    CH-1180 Rolle/VD
    Switzerland
    +41 21 694 10 60
    (Address and telephone number of Registrant’s principal executive offices)

    _________________________


     

    SOPHiA GENETICS, Inc.
    185 Dartmouth Street, Floor 5
    Boston, MA 02116
    United States
    +1 (617) 982-1210
    (Name, address and telephone number of agent for service)

    _________________________

     

    Copies to:
    Deanna L. Kirkpatrick
    Yasin Keshvargar
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, NY 10017
    United States
    +1 (212) 450-4000

    _________________________

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effectiveness of this registration statement.

    If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

    Emerging growth company ☒

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

    † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

    The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until this registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

    EXPLANATORY NOTE

     

    SOPHiA GENETICS SA is filing this Amendment No. 2 to its Registration Statement on Form F-3 (333-280060) (“Amendment No. 2”) as an exhibit-only filing solely to file an updated auditor consent as Exhibit 23.1. This Amendment No. 2 does not modify any provision of the prospectus that forms a part of the Registration Statement. This Amendment No. 2 consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature page, the exhibit index and the exhibit being filed with this Amendment No. 2.

     

     

     

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN THE PROSPECTUS

     

    Item 8.Indemnification of Directors and Officers

     

    Under Swiss law, a corporation may indemnify its directors or officers against losses and expenses (except for such losses and expenses arising from willful misconduct or negligence, although legal scholars advocate that at least gross negligence be required), including attorneys’ fees, judgments, fines and settlement amounts actually and reasonably incurred in a civil or criminal action, suit or proceeding by reason of having been the representative of, or serving at the request of, the corporation.

     

    Subject to Swiss law, our articles of association provide for indemnification of the existing and former members of our board of directors and our executive committee as well as their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and our articles of association require us to advance the expenses of defending any action, suit or proceeding to existing and former members of our board of directors and our executive committee to the extent not included in insurance coverage or advanced by third parties.

     

    In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of their duties under the employment agreement with the company.

     

    We have entered into indemnification agreements with each of the members of our board of directors and executive officers.

     

    Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”) may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the U.S. Securities and Exchange Commission (the “SEC”), such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

     

    Item 9.Exhibits

     

    The following documents are filed as part of this registration statement:

     

        Incorporation by Reference
    Exhibit  No. Description Form File No. Exhibit No. Filing Date
    4.1 Articles of Association 6-K 001-40627 99.1 June 25, 2024
    4.2 Warrant Certificate 6-K 001-40627 99.5 May 7, 2024
    5.1* Opinion of Niederer Kraft Frey Ltd.        
    23.1 Consent of PricewaterhouseCoopers SA, independent registered public accounting firm        
    23.2* Consent of Niederer Kraft Frey Ltd. (included in Exhibit 5.1)        
    24.1* Powers of attorney        
    107* Filing Fee Table        

     

    * Previously filed.

     

    II-1 

     

    Item 10.Undertakings

     

    The undersigned hereby undertakes:

     

    (a)to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (1) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (2) to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and

     

    (3) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1), (a)(2) and (a)(3) of this section do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

     

    (b)that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;

     

    (c)to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering;

     

    (d)to file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (d) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Form F-3;

     

    II-2 

     

    (e)that, for the purpose of determining liability under the Securities Act to any purchaser:

     

    (1) each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

     

    (2) each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; and

     

    (f)that, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

    (1) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

     

    (2) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

     

    (3) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

     

    (4) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser;

     

    The undersigned hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless, in the opinion of its counsel, the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-3 

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the municipality of Rolle, Switzerland on July 22, 2024.

     

      SOPHiA GENETICS SA
       
      By: /s/ Jurgi Camblong
        Name: Jurgi Camblong
        Title: Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons on July 22, 2024 in the capacities indicated:

     

    Name   Title
         
    /s/ Jurgi Camblong  

    Chief Executive Officer and Director

    (principal executive officer)

    Jurgi Camblong  
         
    /s/ Ross Muken  

    Chief Financial Officer

    (principal financial officer and principal accounting officer)

    Ross Muken  
       
    *   Chairman of the Board of Directors
    Troy Cox  
         
    *   Director
    Tomer Berkovitz  
         
    *   Director
    Jean-Michel Cosséry  
         
    *   Director
    Kathy Hibbs  
         
    *   Director
    Didier Hirsch  
         
    *   Director
    Vincent Ossipow  
         
    *   Director
    Lila Tretikov  
         
    /s/ Ross Muken   Authorized Representative in the United States
    Ross Muken  
         
    SOPHiA GENETICS, Inc.    


    * By: /s/ Ross Muken, Ross Muken, as attorney-in-fact

     

     

     

     

    Get the next $SOPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOPH

    DatePrice TargetRatingAnalyst
    12/18/2024$11.00Buy
    Craig Hallum
    8/7/2024$10.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$6.00Buy
    Guggenheim
    11/29/2023$8.00Outperform
    RBC Capital Mkts
    7/5/2023$10.00Overweight
    JP Morgan
    1/3/2023$6.00Buy
    BTIG Research
    11/23/2022$2.00Neutral
    Credit Suisse
    2/15/2022$23.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $SOPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

    BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM™ to analyze complex genomic data at scale.

    2/10/26 9:22:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

    The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.

    1/12/26 7:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology

    BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice. As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and de

    1/7/26 8:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    SEC Filings

    View All

    SEC Form 6-K filed by SOPHiA GENETICS SA

    6-K - SOPHiA GENETICS SA (0001840706) (Filer)

    1/28/26 4:09:30 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by SOPHiA GENETICS SA

    144 - SOPHiA GENETICS SA (0001840706) (Subject)

    1/20/26 4:36:27 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by SOPHiA GENETICS SA

    6-K - SOPHiA GENETICS SA (0001840706) (Filer)

    1/12/26 10:48:12 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on SOPHiA GENETICS SA with a new price target

    Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00

    12/18/24 7:54:16 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS SA downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded SOPHiA GENETICS SA from Overweight to Equal-Weight and set a new price target of $5.00 from $10.00 previously

    8/7/24 11:39:17 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on SOPHiA GENETICS SA with a new price target

    Guggenheim initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00

    6/27/24 7:51:58 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    Financials

    Live finance-specific insights

    View All

    SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance

    BOSTON and ROLLE, Switzerland, Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue was $19.5 million, up 23% year-over-yearGross margin was 66.3% on a reported basis and 73.1% on an adjusted basis, compared to 67.2% reported and 73.1% adjusted in the prior year periodNet IFRS loss was $20.0 million, up 9% year-over-year; Adjusted EBITDA loss was $10.2 million, up 8% year-over-year; Excluding the i

    11/4/25 6:45:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

    Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million.Entered a strategic collaboration with SOPHiA GENETICS (NASDAQ:SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) te

    11/3/25 4:05:00 PM ET
    $MYGN
    $SOPH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025

    BOSTON and ROLLE, Switzerland, Oct. 21, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the

    10/21/25 8:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    Leadership Updates

    Live Leadership Updates

    View All

    SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

    BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

    11/5/24 6:32:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

    New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

    5/30/24 12:19:00 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

    Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology

    5/31/23 9:12:00 AM ET
    $SOPH
    $XYL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Fluid Controls
    Industrials

    $SOPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SOPHiA GENETICS SA

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    11/13/24 3:31:21 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    2/20/24 4:55:59 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    2/14/24 11:23:25 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care